Frontlight ResearchEarly access
TerminatedPhase 2
Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
Key facts
- Who runs it
- Wayne State University
- Where
- Detroit, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 37 people enrolled
- Started
- 1 Feb 2021
- Ended
- 30 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Suvorexant
- Suvorexant Placebo
- Record updated
- 25 September 2024
- Why it stopped
- Did not meet enrollment goals.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age 18-70 years old
- Males and non-pregnant females who agree to medically accepted birth control for the duration of the study
- Meet DSM-5 criteria for opioid use disorder (any severity level) alone or comorbid with stable medical diseases (except for certain medications [see below])
Who cannot take part
- Smoking during the night (11pm-7am). Nicotine replacement therapy is allowed
- Medications including anxiolytics, hypnotics (both prescription and OTC), sedating antidepressants, anticonvulsants, sedating H1 antihistamines (non-sedating second generation H4 antihistamines are allowed), systemic steroids, respiratory stimulants and decongestants, prescription and OTC stimulants, prescription and OTC diet aids, herbal preparations, and narcotic analgesics. All medications and doses will be documented
- Acute/unstable illness: conditions making it unsafe for participation, conditions with potential to disturb sleep (i.e. acute pain, respiratory infection)
- Chronic illnesses; renal failure, liver disease, seizures, and dementing illnesses
- Current psychiatric disease: psychosis, bipolar disorder, PTSD
- Sleep-disordered breathing and periodic leg movements (PLMs) defined as ≥ 10 apnea-hypopneas or PLM events related to EEG arousal per hour of sleep time, or any other primary sleep (e.g. narcolepsy, restless legs syndrome) or circadian disorder
- Body mass index >38
- Night-shift work, which would alter circadian rhythm and be a confound in this trial
Where in United States
- Wayne State UniversityDetroit, United States
About the trial
What the trial wants to find out
Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to investigate whether suvorexant improves outpatient opioid abstinence and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence outcome. 120 participants with opioid use disorder (OUD) will complete this intent-to-treat study.
The 2 groups in the trial
- Suvorexant placeboPlacebo, for comparison
Placebo (inert) tablet
- Suvorexant 20mgTreatment being tested
Suvorexant 20mg tablet
Treatment: Suvorexant
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 September 2024